The CGTLive™ Hematology specialty topic page houses the most up-to-date clinical news coverage in the field of hematology gene and cell therapy. It also includes video interviews with key opinion leaders in the field of hematology/oncology about the latest relevant FDA actions, clinical guideline updates, and clinical trial findings related to the development of cell therapies, gene therapies, and engineered and regenerative medicines for various blood disorders.
December 12th 2024
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial, discussed the latest data update from the CLIMB SCD-121 trial evaluating exa-cel.
Navigating the Next Wave in BTK Inhibition Strategies: Maximizing Clinical Benefit in CLL and MCL, What’s Next...
December 14, 2024
Register Now!
Focusing on Key Updates on the Outlook of Acute Lymphocytic Leukemia (ALL) Management
View More
Oncology Town Hall™: Primary Investigators Present Key Abstracts in CLL from San Diego
View More
Understanding the Recent Developments in Myelodysplastic Syndromes (MDS)
View More
Experts Address the Hottest Topics in AML: Considerations on FLT3, IDH1/2, TP53, Maintenance, Novel Combinations and Beyond!
View More
Medical Crossfire®: Novel BTKi Strategies Transforming Aggressive and Indolent B-Cell Malignancies
View More
The Effect of Recent Updates on the Outlook of Acute Myeloid Leukemia (AML) Management
View More
The Latest Advancements in the Treatment of Chronic Myeloid Leukemia (CML)
View More
Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Treatment of AYA and Adult ALL
View More
Medical Crossfire®: Novel BTKi Strategies Transforming Aggressive and Indolent B-Cell Malignancies
View More
How We Do It®: Novel Biologic Strategies Reshaping Treatment Decision-Making in Pediatric to Adult Hodgkin Lymphoma
View More
Experts Address the Hottest Topics in AML: Considerations on FLT3, IDH1/2, TP53, Maintenance, Novel Combinations and Beyond!
View More
Real-World Applications of Asparaginase Formulations in ALL and LBL From Pediatric/AYA to Adult Treatment: Maximizing Clinical Benefits Through Multidisciplinary Care
View More
How Do We Treat GVHD Today…And Tomorrow? Treatment Algorithms for Key Decision Points in Prophylaxis Care, Acute, and Chronic Disease
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Real-World Applications of Asparaginase Formulations in ALL and LBL From Pediatric/AYA to Adult Treatment: Maximizing Clinical Benefits Through Multidisciplinary Care
View More
Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Treatment of AYA and Adult ALL
View More
Putting Your Stamp on the Next Generation of Care in CML — Improving Outcomes from Frontline to R/R Treatment Settings
View More
Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies and Trials Across GvHD Prophylaxis, Acute, and Chronic Care?
View More
Medical Crossfire®: Bridging Evidence to Practice in AML…Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials
View More
How We Do It®: New Combinations Reshaping Treatment Decision-Making in Newly Diagnosed Multiple Myeloma
View More
Show Me the Data™: Pushing CAR Ts Forward Across Lymphoid Malignancies…Accelerating Access in the Community and the Treatment Strategies for the Road Ahead
View More
Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Ever-Evolving Treatment of MF, PV, and ET
View More
Medical Crossfire®: New Horizons in Acute Lymphoblastic Leukemia—How The Experts Apply New Evidence from AYA to Adult Scenarios
View More
From Barriers to Breakthroughs in Multiple Myeloma: How Trials Compare to the Real-World Management of Patients in Your Practice
View More
Pediatric-Inspired Asparaginase Regimens for Patients With Acute Lymphocytic Leukemia
View More
29th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma
February 27 - March 2, 2025
Register Now!
The Impact of CAR T-Cell Therapy on Hematological Malignancies
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Veit Bücklein, Dr Med, on CAR-T Outcomes Between Male and Female Patients With LBCL
December 16th 2023The postdoctoral researcher at Laboratory for Translational Cancer Immunology, Ludwig-Maximilians-Universität München, discussed the need for research into how CAR T-cells act differently between sexes.
Steven W. Pipe, MD, on Data Continuing to Support Etranacogene Dezaparvovec Over SOC in Hemophilia B
December 12th 2023The professor of pediatric hematology/oncology at CS Mott Children’s Hospital discussed 3-year follow-up data from the HOPE B trial of the approved gene therapy, branded as Hemgenix.
Liso-cel Shows Continued Durability in Long-Term Follow-Up Data of r/r CLL/SLL
December 11th 2023Among patients with chronic lymphocytic leukemia and small lymphocytic lymphoma, the Bristol Myers Squibb CAR T cell product showed consistent efficacy in patients with a lack of success with BTK inhibitor and venetoclax treatment.
Colleen E. Annesley, MD, on Working to Mitigate Inferior Cell Persistence With Manufactured T-APCs
December 11th 2023The medical Director and interim co-Chief Medical Officer at Seattle Children's Therapeutics discussed complete data from the PLAT-03 feasibility trial assessing SCRI-CAR19 and CD19t T-APCs in B-ALL.
Veit Bücklein, Dr Med, on Investigating Sex Differences on CAR T Outcomes in Large B-Cell Lymphoma
December 10th 2023The postdoctoral researcher at Laboratory for Translational Cancer Immunology, Ludwig-Maximilians-Universität München, discussed an analysis of female and male patient outcomes after axi-cel therapy.